Baidu
map

J Neuroinflammation:Met-CCL5能延长狂犬病患者生存

2014-10-02 MedSci MedSci原创

我国学者研究发现了狂犬病病毒感染新靶点——趋化因子CCL5,该因子的拮抗剂有望成为延长狂犬病患者生存时间的潜在药物。相关研究论文日前在线发表在国际学术刊物《神经炎症杂志》上。狂犬病病毒感染引发人类和动物严重的中枢神经系统功能障碍,具有极高的死亡率。尽管狂犬疫苗能有效预防病毒感染,但对于未注射疫苗的感染患者仍缺乏有效的治疗手段,每年全球仍有5.5万名患者死于狂犬病。中科院上海生命科学研究院生物化学与

我国学者研究发现了狂犬病病毒感染新靶点——趋化因子CCL5,该因子的拮抗剂有望成为延长狂犬病患者生存时间的潜在药物。相关研究论文日前在线发表在国际学术刊物《神经炎症杂志》上。

狂犬病病毒感染引发人类和动物严重的中枢神经系统功能障碍,具有极高的死亡率。尽管狂犬疫苗能有效预防病毒感染,但对于未注射疫苗的感染患者仍缺乏有效的治疗手段,每年全球仍有5.5万名患者死于狂犬病。

中科院上海生命科学研究院生物化学与细胞生物学研究所王红艳研究组与中国疾病预防控制中心唐青研究组合作,通过分析不同毒力狂犬病病毒的毒株感染的乳鼠和成年鼠,发现狂犬病病毒感染后期即濒死前的小鼠,中枢神经系统出现巨噬细胞和淋巴细胞浸润及炎症反应,并与显著升高的趋化因子CCL5紧密相关。科研人员再通过向其脑部注射外源性趋化因子CCL5,发现CCL5促进免疫细胞通过FAK/AKT的信号通路,定向迁移至中枢神经系统,提高促炎因子产生,并加重神经细胞的凋亡。

科研人员进一步研究发现,在利用外源性趋化因子CCL5的拮抗剂即Met-CCL5处理狂犬病病毒感染乳鼠或成年鼠后,显著降低了中枢神经系统的炎症反应,进而延长感染小鼠的生存时间。

原始出处:
Huang Y, Jiao S, Tao X, Tang Q, Jiao W, Xiao J, Xu X, Zhang Y, Liang G, Wang H.Met-CCL5 represents an immunotherapy strategy to ameliorate rabies virus infection. J Neuroinflammation. 2014 Aug 21;11(1):146

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2057574, encodeId=ea41205e57495, content=<a href='/topic/show?id=c02b106e29a' target=_blank style='color:#2F92EE;'>#LAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10672, encryptionId=c02b106e29a, topicName=LAM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Thu Jan 15 23:36:00 CST 2015, time=2015-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932509, encodeId=bd72193250934, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sat Sep 05 22:36:00 CST 2015, time=2015-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895744, encodeId=ad251895e4473, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed May 13 10:36:00 CST 2015, time=2015-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412828, encodeId=59f21412828f3, content=<a href='/topic/show?id=28d868090c7' target=_blank style='color:#2F92EE;'>#狂犬病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68090, encryptionId=28d868090c7, topicName=狂犬病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b512907439, createdName=luoxiaog, createdTime=Sat Oct 04 06:36:00 CST 2014, time=2014-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1454799, encodeId=39261454e99f1, content=<a href='/topic/show?id=ca5f12e51d4' target=_blank style='color:#2F92EE;'>#NFL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12751, encryptionId=ca5f12e51d4, topicName=NFL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90805606164, createdName=xiaoyeshuang, createdTime=Sat Oct 04 06:36:00 CST 2014, time=2014-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545552, encodeId=ce7b1545552c1, content=<a href='/topic/show?id=7c4c984645' target=_blank style='color:#2F92EE;'>#inflammation#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9846, encryptionId=7c4c984645, topicName=inflammation)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffd513772211, createdName=ms6980045490879608, createdTime=Sat Oct 04 06:36:00 CST 2014, time=2014-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631343, encodeId=56d71631343fd, content=<a href='/topic/show?id=e210421640' target=_blank style='color:#2F92EE;'>#CCL5#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4216, encryptionId=e210421640, topicName=CCL5)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63d621719915, createdName=lingqf, createdTime=Sat Oct 04 06:36:00 CST 2014, time=2014-10-04, status=1, ipAttribution=)]
    2015-01-15 lxg951
  2. [GetPortalCommentsPageByObjectIdResponse(id=2057574, encodeId=ea41205e57495, content=<a href='/topic/show?id=c02b106e29a' target=_blank style='color:#2F92EE;'>#LAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10672, encryptionId=c02b106e29a, topicName=LAM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Thu Jan 15 23:36:00 CST 2015, time=2015-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932509, encodeId=bd72193250934, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sat Sep 05 22:36:00 CST 2015, time=2015-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895744, encodeId=ad251895e4473, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed May 13 10:36:00 CST 2015, time=2015-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412828, encodeId=59f21412828f3, content=<a href='/topic/show?id=28d868090c7' target=_blank style='color:#2F92EE;'>#狂犬病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68090, encryptionId=28d868090c7, topicName=狂犬病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b512907439, createdName=luoxiaog, createdTime=Sat Oct 04 06:36:00 CST 2014, time=2014-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1454799, encodeId=39261454e99f1, content=<a href='/topic/show?id=ca5f12e51d4' target=_blank style='color:#2F92EE;'>#NFL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12751, encryptionId=ca5f12e51d4, topicName=NFL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90805606164, createdName=xiaoyeshuang, createdTime=Sat Oct 04 06:36:00 CST 2014, time=2014-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545552, encodeId=ce7b1545552c1, content=<a href='/topic/show?id=7c4c984645' target=_blank style='color:#2F92EE;'>#inflammation#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9846, encryptionId=7c4c984645, topicName=inflammation)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffd513772211, createdName=ms6980045490879608, createdTime=Sat Oct 04 06:36:00 CST 2014, time=2014-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631343, encodeId=56d71631343fd, content=<a href='/topic/show?id=e210421640' target=_blank style='color:#2F92EE;'>#CCL5#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4216, encryptionId=e210421640, topicName=CCL5)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63d621719915, createdName=lingqf, createdTime=Sat Oct 04 06:36:00 CST 2014, time=2014-10-04, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2057574, encodeId=ea41205e57495, content=<a href='/topic/show?id=c02b106e29a' target=_blank style='color:#2F92EE;'>#LAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10672, encryptionId=c02b106e29a, topicName=LAM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Thu Jan 15 23:36:00 CST 2015, time=2015-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932509, encodeId=bd72193250934, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sat Sep 05 22:36:00 CST 2015, time=2015-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895744, encodeId=ad251895e4473, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed May 13 10:36:00 CST 2015, time=2015-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412828, encodeId=59f21412828f3, content=<a href='/topic/show?id=28d868090c7' target=_blank style='color:#2F92EE;'>#狂犬病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68090, encryptionId=28d868090c7, topicName=狂犬病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b512907439, createdName=luoxiaog, createdTime=Sat Oct 04 06:36:00 CST 2014, time=2014-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1454799, encodeId=39261454e99f1, content=<a href='/topic/show?id=ca5f12e51d4' target=_blank style='color:#2F92EE;'>#NFL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12751, encryptionId=ca5f12e51d4, topicName=NFL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90805606164, createdName=xiaoyeshuang, createdTime=Sat Oct 04 06:36:00 CST 2014, time=2014-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545552, encodeId=ce7b1545552c1, content=<a href='/topic/show?id=7c4c984645' target=_blank style='color:#2F92EE;'>#inflammation#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9846, encryptionId=7c4c984645, topicName=inflammation)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffd513772211, createdName=ms6980045490879608, createdTime=Sat Oct 04 06:36:00 CST 2014, time=2014-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631343, encodeId=56d71631343fd, content=<a href='/topic/show?id=e210421640' target=_blank style='color:#2F92EE;'>#CCL5#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4216, encryptionId=e210421640, topicName=CCL5)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63d621719915, createdName=lingqf, createdTime=Sat Oct 04 06:36:00 CST 2014, time=2014-10-04, status=1, ipAttribution=)]
    2015-05-13 一闲
  4. [GetPortalCommentsPageByObjectIdResponse(id=2057574, encodeId=ea41205e57495, content=<a href='/topic/show?id=c02b106e29a' target=_blank style='color:#2F92EE;'>#LAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10672, encryptionId=c02b106e29a, topicName=LAM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Thu Jan 15 23:36:00 CST 2015, time=2015-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932509, encodeId=bd72193250934, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sat Sep 05 22:36:00 CST 2015, time=2015-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895744, encodeId=ad251895e4473, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed May 13 10:36:00 CST 2015, time=2015-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412828, encodeId=59f21412828f3, content=<a href='/topic/show?id=28d868090c7' target=_blank style='color:#2F92EE;'>#狂犬病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68090, encryptionId=28d868090c7, topicName=狂犬病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b512907439, createdName=luoxiaog, createdTime=Sat Oct 04 06:36:00 CST 2014, time=2014-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1454799, encodeId=39261454e99f1, content=<a href='/topic/show?id=ca5f12e51d4' target=_blank style='color:#2F92EE;'>#NFL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12751, encryptionId=ca5f12e51d4, topicName=NFL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90805606164, createdName=xiaoyeshuang, createdTime=Sat Oct 04 06:36:00 CST 2014, time=2014-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545552, encodeId=ce7b1545552c1, content=<a href='/topic/show?id=7c4c984645' target=_blank style='color:#2F92EE;'>#inflammation#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9846, encryptionId=7c4c984645, topicName=inflammation)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffd513772211, createdName=ms6980045490879608, createdTime=Sat Oct 04 06:36:00 CST 2014, time=2014-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631343, encodeId=56d71631343fd, content=<a href='/topic/show?id=e210421640' target=_blank style='color:#2F92EE;'>#CCL5#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4216, encryptionId=e210421640, topicName=CCL5)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63d621719915, createdName=lingqf, createdTime=Sat Oct 04 06:36:00 CST 2014, time=2014-10-04, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2057574, encodeId=ea41205e57495, content=<a href='/topic/show?id=c02b106e29a' target=_blank style='color:#2F92EE;'>#LAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10672, encryptionId=c02b106e29a, topicName=LAM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Thu Jan 15 23:36:00 CST 2015, time=2015-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932509, encodeId=bd72193250934, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sat Sep 05 22:36:00 CST 2015, time=2015-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895744, encodeId=ad251895e4473, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed May 13 10:36:00 CST 2015, time=2015-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412828, encodeId=59f21412828f3, content=<a href='/topic/show?id=28d868090c7' target=_blank style='color:#2F92EE;'>#狂犬病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68090, encryptionId=28d868090c7, topicName=狂犬病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b512907439, createdName=luoxiaog, createdTime=Sat Oct 04 06:36:00 CST 2014, time=2014-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1454799, encodeId=39261454e99f1, content=<a href='/topic/show?id=ca5f12e51d4' target=_blank style='color:#2F92EE;'>#NFL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12751, encryptionId=ca5f12e51d4, topicName=NFL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90805606164, createdName=xiaoyeshuang, createdTime=Sat Oct 04 06:36:00 CST 2014, time=2014-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545552, encodeId=ce7b1545552c1, content=<a href='/topic/show?id=7c4c984645' target=_blank style='color:#2F92EE;'>#inflammation#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9846, encryptionId=7c4c984645, topicName=inflammation)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffd513772211, createdName=ms6980045490879608, createdTime=Sat Oct 04 06:36:00 CST 2014, time=2014-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631343, encodeId=56d71631343fd, content=<a href='/topic/show?id=e210421640' target=_blank style='color:#2F92EE;'>#CCL5#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4216, encryptionId=e210421640, topicName=CCL5)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63d621719915, createdName=lingqf, createdTime=Sat Oct 04 06:36:00 CST 2014, time=2014-10-04, status=1, ipAttribution=)]
    2014-10-04 xiaoyeshuang
  6. [GetPortalCommentsPageByObjectIdResponse(id=2057574, encodeId=ea41205e57495, content=<a href='/topic/show?id=c02b106e29a' target=_blank style='color:#2F92EE;'>#LAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10672, encryptionId=c02b106e29a, topicName=LAM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Thu Jan 15 23:36:00 CST 2015, time=2015-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932509, encodeId=bd72193250934, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sat Sep 05 22:36:00 CST 2015, time=2015-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895744, encodeId=ad251895e4473, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed May 13 10:36:00 CST 2015, time=2015-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412828, encodeId=59f21412828f3, content=<a href='/topic/show?id=28d868090c7' target=_blank style='color:#2F92EE;'>#狂犬病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68090, encryptionId=28d868090c7, topicName=狂犬病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b512907439, createdName=luoxiaog, createdTime=Sat Oct 04 06:36:00 CST 2014, time=2014-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1454799, encodeId=39261454e99f1, content=<a href='/topic/show?id=ca5f12e51d4' target=_blank style='color:#2F92EE;'>#NFL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12751, encryptionId=ca5f12e51d4, topicName=NFL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90805606164, createdName=xiaoyeshuang, createdTime=Sat Oct 04 06:36:00 CST 2014, time=2014-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545552, encodeId=ce7b1545552c1, content=<a href='/topic/show?id=7c4c984645' target=_blank style='color:#2F92EE;'>#inflammation#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9846, encryptionId=7c4c984645, topicName=inflammation)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffd513772211, createdName=ms6980045490879608, createdTime=Sat Oct 04 06:36:00 CST 2014, time=2014-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631343, encodeId=56d71631343fd, content=<a href='/topic/show?id=e210421640' target=_blank style='color:#2F92EE;'>#CCL5#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4216, encryptionId=e210421640, topicName=CCL5)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63d621719915, createdName=lingqf, createdTime=Sat Oct 04 06:36:00 CST 2014, time=2014-10-04, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2057574, encodeId=ea41205e57495, content=<a href='/topic/show?id=c02b106e29a' target=_blank style='color:#2F92EE;'>#LAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10672, encryptionId=c02b106e29a, topicName=LAM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Thu Jan 15 23:36:00 CST 2015, time=2015-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932509, encodeId=bd72193250934, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sat Sep 05 22:36:00 CST 2015, time=2015-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895744, encodeId=ad251895e4473, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed May 13 10:36:00 CST 2015, time=2015-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412828, encodeId=59f21412828f3, content=<a href='/topic/show?id=28d868090c7' target=_blank style='color:#2F92EE;'>#狂犬病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68090, encryptionId=28d868090c7, topicName=狂犬病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b512907439, createdName=luoxiaog, createdTime=Sat Oct 04 06:36:00 CST 2014, time=2014-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1454799, encodeId=39261454e99f1, content=<a href='/topic/show?id=ca5f12e51d4' target=_blank style='color:#2F92EE;'>#NFL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12751, encryptionId=ca5f12e51d4, topicName=NFL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90805606164, createdName=xiaoyeshuang, createdTime=Sat Oct 04 06:36:00 CST 2014, time=2014-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545552, encodeId=ce7b1545552c1, content=<a href='/topic/show?id=7c4c984645' target=_blank style='color:#2F92EE;'>#inflammation#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9846, encryptionId=7c4c984645, topicName=inflammation)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffd513772211, createdName=ms6980045490879608, createdTime=Sat Oct 04 06:36:00 CST 2014, time=2014-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631343, encodeId=56d71631343fd, content=<a href='/topic/show?id=e210421640' target=_blank style='color:#2F92EE;'>#CCL5#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4216, encryptionId=e210421640, topicName=CCL5)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63d621719915, createdName=lingqf, createdTime=Sat Oct 04 06:36:00 CST 2014, time=2014-10-04, status=1, ipAttribution=)]
    2014-10-04 lingqf

相关资讯

102个国家和地区有动物狂犬病流行

  国家质检总局近日发布的疫情警告提示,据世界动物卫生组织统计,截至今年10月底,共有102个国家和地区有动物狂犬病流行。自2011年8月以来,先后有洪都拉斯、玻利维亚、荷兰等国提交疫情紧急报告,此轮疫情至今仍未停息。   在102个有动物狂犬病流行的国家和地区中,法国、俄罗斯、加拿大、美国、巴西、印度尼西亚、以色列、韩国、菲律宾、沙特阿拉伯、泰国、南非等85个国家和地区在家养动物或野生动物中发

狂犬病已在102个国家流行 中国已有动物病例

  国家质检总局近日发布的疫情警告提示,据世界动物卫生组织统计,截至今年10月底,共有102个国家和地区有动物狂犬病流行。自2011年8月以来,先后有洪都拉斯、玻利维亚、荷兰等国提交疫情紧急报告,此轮疫情至今仍未停息。   在102个有动物狂犬病流行的国家和地区中,法国、俄罗斯、加拿大、美国、巴西、印度尼西亚、以色列、韩国、菲律宾、沙特阿拉伯、泰国、南非等85个国家和地区在家养动物或野生动物中发

science:蝙蝠提示控制预防疾病的方法

英国格拉斯哥大学的 Daniel G. Streicker是科学与生命科学实验室(SciLife Lab)年轻科学家奖国际竞赛的2013年度大奖(Grand Prize)的得主,他主要的研究方向是揭示有关跨物种病毒传播的起源及频率的模式。相关文章发表于2013年12月06日的science杂志上。 Daniel G.&nbs

狂犬病肺结核报告死亡均创新高

  卫生部日前发布的9月全国疫情报告数据显示,当月全国(不含台港澳)法定报告传染病报告发病数再度较上月大幅度减少,总计报告发病数减少了47711例,但报告死亡数增加了277例。其中,艾滋病报告死亡突破1100例,狂犬病、肺结核报告死亡数达到了今年以来的最高。   根据卫生部通报,全国9月甲类传染病报告发病8例(鼠疫1例,霍乱7例),死亡1人(鼠疫患者)。乙类传染病报告发病数居前五位的病种依次为病

密尔沃基疗法治狂犬病再获成功

  美国加利福尼亚州北部的一名8岁狂犬病患者近日接受一种名为密尔沃基疗法的诱导昏迷治疗后成功康复,迄今全球已有5名未接种疫苗的狂犬病患者经这种疗法治疗后康复。   实施此次治疗的加利福尼亚大学戴维斯分校儿童医院报告说,这名8岁女童在被一只流浪猫抓伤数周后出现病毒性脑炎症状,后被诊断为因狂犬病病毒引发病毒性脑炎。于是,医生开始以密尔沃基疗法尝试挽救患儿。   这种疗法于2004年由美国研究人员推

Baidu
map
Baidu
map
Baidu
map